Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit

Stock Information for PAVmed Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PAVmed Inc.

PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
PAVmed Provides Business Update and Third Quarter Financial Results
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.